ArticleThorax2004
Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis.
Article in Thorax, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 4 syntheses or guidelines pooled it, 252 citations in OpenAlex.
- Antibiotic therapy for chronic infection with <I>Burkholderia cepacia</I> complex in people with cystic fibrosis.The Cochrane database of systematic reviews · 2021Pooled it
- Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation.The Cochrane database of systematic reviews · 2020Pooled it
- Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis.The Cochrane database of systematic reviews · 2019Pooled it
- Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation.The Cochrane database of systematic reviews · 2016Pooled it
- Ecological Diversity, Metabolic Versatility, and Biotechnological Applications ofAntibiotics (Basel, Switzerland) · 2025Review
- Cyclic di AMP phosphodiesterase nanovaccine elicits protective immunity against Burkholderia cenocepacia infection in mice.NPJ vaccines · 2025Article
- Antisense phosphorodiamidate morpholino oligomers retain activity inFrontiers in microbiology · 2025Article
- Isolation ofERJ open research · 2024Article
- Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis.Clinical microbiology reviews · 2024Review
- Mutations Affecting Cellular Levels of Cobalamin (Vitamin BJournal of microbiology and biotechnology · 2024Article
- Article
- Glycoproteomic and proteomic analysis ofMicrobiology spectrum · 2024Article
- Article
- Cloaking antibodies are prevalent inFrontiers in cellular and infection microbiology · 2024Article
- Phage therapy to treat cystic fibrosisFrontiers in microbiology · 2024Review
- Synergistic Interactions amongMicrobiology spectrum · 2023Article
- [Journal of medicinal chemistry · 2023Article
- Eradication ofERJ open research · 2023Article
- Phage-antibiotic synergy reduces Burkholderia cenocepacia population.BMC microbiology · 2023Article
- Nebulized levofloxacin for chronicRespiratory medicine case reports · 2022Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBurkholderia cepacia infection has been associated with a poor prognosis for patients with cystic fibrosis (CF). It is now recognised that organisms classified as B cepacia comprise a number of distinct genomic species each known as a genomovar of the B cepacia complex (BCC). The outcome of infection for CF patients with individual genomovars is unknown. The clinical outcome of infection with the two most commonly isolated genomovars (B cenocepacia and B multivorans) was studied at a specialist CF centre between 1982 and 2003.
methodsThe numbers of patients who progressed from initial to chronic infection were assessed. Control groups were created by matching patients with chronic BCC infection by percentage forced expiratory volume in 1 second with patients with Pseudomonas aeruginosa infection. Outcome measures were survival time, deaths from "cepacia syndrome", rate of decline in spirometry and body mass index (BMI), and treatment requirements.
resultsForty nine patients had an initial infection with either B multivorans (n = 16) or B cenocepacia (n = 33); 8/16 and 31/33, respectively, developed chronic infection (p<0.001). Deaths from "cepacia syndrome" occurred in both BCC groups. Patients with B cenocepacia infection had a shorter survival than patients with P aeruginosa infection (p = 0.01). There was no difference in survival between CF patients infected with B multivorans and P aeruginosa. There were no observed differences in changes in spirometry and BMI or treatment requirements between the BCC groups and respective controls.
conclusionIn CF, the genomovar status of BCC may influence both the likelihood of progression from initial to chronic infection and the overall survival of the patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.